People · Operator
Named in public records as an officer, director or promoter · active 2009–2026 · Pharmaceuticals, Medical Devices
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aclaris Therapeutics, Inc. | — | Pharmaceuticals | Series C | $192.5M | $611.8M | 2012 |
| Velicept Therapeutics, Inc. | — | Pharmaceuticals | Series B | $39.9M | $204.0M | 2015 |
| NexEos Diagnostics, Inc. | — | Medical Devices | Series A | $25.7M | $7.9M | 2019 |
| Vicept Therapeutics, Inc. | — | Pharmaceuticals | Series B | $22.0M | $536.9M | 2009 |
| Yaupon Therapeutics Inc | — | Pharmaceuticals | Series A | $21.6M | $256.8M | 2011 |
| Ralexar Therapeutics, Inc. | — | Pharmaceuticals | Series A | $19.0M | $132.5M | 2014 |
| Onspira Therapeutics, Inc. | — | Pharmaceuticals | Seed | $1.9M | $73.2M | 2017 |
Stephen Tullman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Stephen Tullman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Douglas Gessl | 4 | 4 |
| Albert Cha | 3 | 9 |
| Neal Walker | 3 | 5 |
| Kamil Ali-Jackson | 3 | 3 |
| ANAND MEHRA | 2 | 7 |
| Christopher Powala | 2 | 3 |
| Christopher Molineaux | 2 | 2 |
| Somu Subramaniam | 1 | 17 |
| David Hirsch | 1 | 16 |
| James Walker | 1 | 16 |
| Ketan Patel | 1 | 10 |
| Dennis Langer | 1 | 9 |
| David Gordon | 1 | 8 |
| Thomas Beck | 1 | 7 |
| James Huang | 1 | 5 |
| Andrew Schiff | 1 | 5 |
| Somasundaram Subramaniam | 1 | 5 |
| Jason Hong | 1 | 4 |
| Jeff Himawan | 1 | 4 |
| Raju Mohan | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.